

# Leishmaniasis Country Profile Generator

## User Manual

The Leishmaniasis Country Profile Generator, from now LCPG, retrieves country data from several sources for a specific year and puts it in an HTML country profile format ready to print in PDF.

## Table of Contents

<b>1. METADATA AND PERMISSIONS REQUIREMENTS.....</b>	<b>2</b>
<b>2. GENERATING A COUNTRY PROFILE.....</b>	<b>3</b>
2.1 CONFIGURATION PANEL .....	4
2.1.1 <i>General</i> .....	4
2.2.2 <i>Maps</i> .....	5
2.2.3 <i>Footnotes</i> .....	6
2.2 COUNTRY PROFILE.....	7
2.2.1 <i>Edit elements in the CP</i> .....	7
2.2.2 <i>Footnote elements in the CP</i> .....	7
2.2.3 <i>Arrange maps and charts</i> .....	7
2.2.4 <i>Printing the CP or saving it as PDF</i> .....	8
<b>3. SOURCE OF INFORMATION IN COUNTRY PROFILE SECTIONS.....</b>	<b>9</b>
3.1 COUNTRY GENERAL INFORMATION SECTION.....	9
3.2 EPIDEMIOLOGY SECTION .....	11
3.3 MONTHLY DISTRIBUTION OF NEW CASES JANUARY-DECEMBER SECTION .....	14
3.4 MAPS SECTION .....	15
3.5 CONTROL AND SURVEILLANCE SECTION .....	16
3.6 DIAGNOSIS SECTION .....	17
3.7 TREATMENT AND MEDICINES AND TREATMENT OUTCOME SECTION.....	19


# 1. Metadata and permissions requirements

LCPG and the user using it need metadata (and eventually) data read access to the following metadata:

Type	ID	Name	Comments
program	w9hSFsNr3Vh	CL_cases_by provenance	
program	NVUljZlakuO	Footnotes for Report Generator RG_	Needs to be assigned to the country
program	Jd8gnElt8uT	Leishmaniasis endemicity	Needs to be assigned to the country
program	i5JSf4ffFI2	VL_cases_by provenance	
dataSet	Uc3j0vpsfSB	Cutaneous Leishmaniasis - ACL/ZCL - Detailed aggregated - Annual	
dataSet	Sn0dExPzQqW	Cutaneous Leishmaniasis - ACL/ZCL - Simple aggregated - Annual	
dataSet	tnek2Ljfulm	Cutaneous Leishmaniasis - Detailed aggregated - Annual	
dataSet	zna8KFLMXn4	Cutaneous Leishmaniasis - Simple aggregated - Annual	
dataSet	NKWbkXyfO5F	General information	Needs to be assigned to the country
dataSet	p0NhulUoeST	GHO indicators for NTDs	Needs to be assigned to the country
dataSet	fdBM4sWSuPR	Visceral Leishmaniasis - Detailed aggregated - Annual	
dataSet	SHw2zOysJ1R	Visceral Leishmaniasis - Simple aggregated - Annual	
sqlViews	mejiVo59hWs	categoryOptionCombos in DS	
sqlViews	oQdlVqkVlxC	data elements in dataSet	
sqlViews	lrawAndH02Y	data elements used in program	
legendSet	clwSlrqvmMx	ACL Incidence	
legendSet	TnU2O8YxH51	CL Incidence	
legendSet	gUOjExXros1	VL Incidence	
legendSet	TbrqpLWzLS8	ZCL Incidence	
indicatorGroup	nozEoB0uRq9	NTD_Leish_CP_INC_charts_IG	It doesn't need the IG itself but its indicators.
indicatorGroup	VvTNYst2QCW	NTD_Leish_CP_maps_IG	It doesn't need the IG itself but its indicators.
indicatorGroup	KUdeVRtlK45	NTD_Leish_CP_popAtRisk_IG	It doesn't need the IG itself but its indicators.

## 2. Generating a country profile

Look for the app called “Leishmaniasis Country Profile Generator” in the apps bar of the WIDP instance.



A form box like the following will appear

### Generate Country Profile

Year

Country

Start preparing CP

### Generate Country Profile

Year

Country

People's Democratic Republic of Algeria  
Republic of Albania

Start preparing CP

Start typing a year and a country. Once it starts appearing in the list, select it. This selection is needed, otherwise, the system won't take in account the text you typed.

The LCPG has two main sections: The configuration panel and the country profile itself.

Configuration Area - Wort be printed  
Instructions : Left click to add a footnote number  
Right click to edit an element.

General Maps Footnotes

Leishmaniasis types to show:

☒ VL ☐ CL ☒ AZCL ☒ ZCL ☐ PKDL ☒ MCL

Leishmaniasis types to show in monthly table:

☒ VL ☐ CL ☐ VL (previous year) ☐ CL (previous year) ☒ AZCL ☒ ZCL

☐ ACL (previous year) ☐ ZCL (previous year)

Graphs to show:

☐ CL monthly ☒ AZCL monthly ☒ VL monthly

☐ CL yearly ☒ AZCL yearly ☒ VL yearly

2nd sub-national administ...

World Health Organization

Leishmaniasis People's Democratic Republic of Algeria 2017  
Published in July 2019

Country General Information

Total population:	10 000 000	Age group <15/> 14 years, %:	40% / 60%
Gender (% F/M):	25.5% / 24.5%	Life expectancy at birth in years (F/M):	75 / 68
GDP (PPP int \$):	5000	Number of 2nd sub-national administrative level divisions, name:	1493, Abadla
Income status:	Lower middle income		

Epidemiology

	VL	ACL	ZCL	MCL
--	----	-----	-----	-----

Endemicity status:

Configuration panel

Country profile

## 2.1 Configuration panel

In this panel you can configure which elements are showing in the CP and how. It has three tabs: General, to manage which types of the disease will appear in the tables, the graphs and the subnational level taken in account; maps to configure maps, legends and “notas bene”; and Footnotes, to manage which footnotes will appear in the CP.

### 2.1.1 General

The screenshot shows the 'General' configuration panel. It has three tabs: 'General', 'Maps', and 'Footnotes'. The 'General' tab is selected. The panel is divided into three main sections, each with a title and a set of checkboxes:

- Leishmaniasis types to show:** This section contains checkboxes for VL (checked), CL, ACL, ZCL, PKDL, and MCL.
- Leishmaniasis types to show in monthly table:** This section contains checkboxes for VL (checked), VL (previous year), CL, CL (previous year), ACL, ACL (previous year), ZCL, and ZCL (previous year).
- Graphs to show:** This section contains checkboxes for CL monthly, AZCL monthly, VL monthly (checked), CL yearly, AZCL yearly, and VL yearly (checked).

At the bottom of the panel, there is a dropdown menu labeled '1st sub-national administr...' and a checkbox labeled 'recalculate maps to this level' which is checked.

Leishmaniasis types to show are checked if, at least, one leishmaniasis dataset of this type (VL, CL or ACL/ZCL) is assigned to the country. PKDL and MCL are unchecked by default.

The behavior is the same in the monthly table checkboxes except for previous years, whose checkboxes are by default unchecked.

The graphs checkboxes follow also the same logic.

The subnational level dropdown menu is set, by default, to the first subnational level. Changing it to 2<sup>nd</sup> or 3<sup>rd</sup> subnational level will update:

- The “Number of endemic X sub-national...” row text-and-value in the Country General Information section.
- The “Number of endemic X sub-national...” row text-and-value in the Epidemiology section.
- All the maps if the “recalculate maps to this level” checkbox is checked.

## 2.2.2 Maps

As in the previous tab, the maps checkboxes follow the same logic of the previous other checkboxes.

The screenshot shows a configuration window with three tabs: 'General', 'Maps' (selected), and 'Footnotes'. The 'Maps' tab contains two main sections: 'Maps to show' and 'Configure map'.

**Maps to show:** This section has four checkboxes: 'VL incidence' (checked), 'CL incidence', 'ACL incidence', and 'ZCL incidence'.

**Configure map:** This section contains several controls:

- Select a Map:** A dropdown menu.
- OrgUnit levels:** A dropdown menu showing 'WHO Member States - Level 1'.
- OSM Light:** A dropdown menu.
- Opacity:** A slider set to 80.
- Height:** A slider set to 315.
- Width:** A slider set to 420.
- Update Map:** A button.
- Select a Legend:** A dropdown menu.
- Font size:** A text input field.
- Update Legend:** A button.
- Resize Nota Bene for Maps:** Two radio buttons, 'Disabled' (selected) and 'Enabled'.
- Resize Nota Bene:** Two radio buttons, 'Disabled' (selected) and 'Enabled'.

To update a map, select a map name on the dropdown. Select the deepest subnational level you want to see drawn in the map. You can select also the background layout, the opacity, the height and the width. Click “Update Map” once you finished the configuration.

You can relocate and resize the legend within the map. To do that, select a legend on the right dropdown menu. You will see appear the legend at right. You can resize it, edit the text or select the corner where it will be shown. Click “Update Legend” to apply changes.

Size of the two “Nota Bene” in the CP are locked by default. You may enable this feature to adapt the size of the box to the content or the location. Remember putting them back to “disabled” once you have finished.

## 2.2.3 Footnotes

General

Maps

Footnotes

Stored footnotes

Defined as "In this reporting period, an area at the 3rd sub-national administrative level reporting cases for the first time ever"

Defined as "Number of people living in 3rd sub-national administrative level endemic areas"

Defined as "In this reporting period, an area at the 2nd sub-national administrative level reporting cases for the first time ever"

Defined as "Number of people living in 2nd sub-national administrative level endemic areas"

Defined as "In this reporting period,

Footnotes page 1

1 Defined as "In this reporting period, an area at the 3rd sub-national administrative level reporting cases for the first time ever"

2 Defined as "Number of people living in 3rd sub-national administrative level endemic areas"

3 Relapse in this country is defined as: "a patient who experiences recurrence of VL symptoms with parasitological confirmation at any time point after initial cure"

Footnotes page 2

4 Failure in this country is defined as: "signs and symptoms persist or recur during treatment or up to initial treatment outcome assessment"


In this section you organize the footnotes stored in and got from the footnote program.

To move one footnote from one page to another or to remove from the CP, just drag and drop it in the correct box. You can reorder them within the box. The footnote index will be accordingly updated. However, the index you put in the CP text are not "linked" to these footnotes: It's up to you to make sure the reference and the index match.

## 2.2 Country profile


### 2.2.1 Edit elements in the CP

You can edit almost any text in the CP. To do that, just right click on the element and an edit field box will pop up. You can change the text, color, size, text style, add hyperlinks, etc.



### 2.2.2 Footnote elements in the CP



You can footnote almost any element of the CP by left clicking on the element. A footnote index (1 for first clicked element) will be added to the element. The next element will be footnoted with the number “2” and so on. If you want to remove a footnote index, just left click again on it. It’s better to remove all higher footnote indexes first, to keep a logic sequence of indexes.



### 2.2.3 Arrange maps and charts

Charts and maps can be moved by clicking on them and moving the mouse to the desired location.

In addition, maps can be zoomed in and its content moved up, down, left or right. However, they cannot be zoomed out for the instance. If you need to reset a map, just go to the maps section in the configuration zone, select the map and click on “Update map”.



## 2.2.4 Printing the CP or saving it as PDF

In order to generate the PDF version of the CP, click ctrl+P. You can adjust the final with the parameters: paper size (A4) scale (normally 100%), margins (minimum or custom). Select your printer or the option “Save as PDF”.

The screenshot displays a web application interface for a Country Profile (CP) of Nepal, with a print settings dialog open on the right.

**Country Profile (CP) for Nepal:**

- Header:** 0.1" (top left), 1 (top center), 2 sheets of paper (top right).
- Section: COUNTRY GENERAL INFORMATION**
  - Endemic status: VL
  - Number of new cases (incidence): 247
  - Number of relapse cases: 5
  - Total number of cases: 252
  - Imported cases (R, %): 10, 4%
  - Gender distribution (M/F): 34%
  - Age group distribution (% <5-14-14-): (4, 18, 78)
  - Incidence rate (cases/10 000 population in endemic areas): -
  - Number of endemic 1st sub-national administrative level divisions (n): No data
  - Population at risk (% <100%): - 5 / No data
  - Was there any outbreak? No
  - Number of new foci? No data
- Section: EPIDEMIOLOGY**
  - Endemic status: VL
  - Number of new cases (incidence): 247
  - Number of relapse cases: 5
  - Total number of cases: 252
  - Imported cases (R, %): 10, 4%
  - Gender distribution (M/F): 34%
  - Age group distribution (% <5-14-14-): (4, 18, 78)
  - Incidence rate (cases/10 000 population in endemic areas): -
  - Number of endemic 1st sub-national administrative level divisions (n): No data
  - Population at risk (% <100%): - 5 / No data
  - Was there any outbreak? No
  - Number of new foci? No data
- Section: Distribution of new cases January-December**
  - Number of new (primary) VL cases reported by month in 2015 and 2016
  - Line graph showing VL cases (2015) and VL cases (2016) from JAN to DEC.
  - Bar chart showing VL incidence rate (2015) and VL cases (2016) from JAN to DEC.
- Footer:** 0.1" (bottom left), 0.15" (bottom center), 0.15" (bottom right).

**Print Settings Dialog:**

- Print** (top left), **2 sheets of paper** (top right).
- Color** (dropdown menu).
- More settings** (dropdown menu).
- Paper size** (dropdown menu, A4).
- Pages per sheet** (dropdown menu, 1).
- Margins** (dropdown menu, Custom).
- Quality** (dropdown menu, 120 dpi).
- Scale** (dropdown menu, Custom).
- Options**
  - ☐ Headers and footers
  - ☐ Background graphics
- Print** (button), **Cancel** (button).



### 3. Source of information in country profile sections

#### 3.1 Country general information section

B1	COUNTRY GENERAL INFORMATION			
B2	Total population:	41,320,000	B5	Age group <15/> 14 years, %: 0% / 0%
B3	Gender (% , F/M):	0% / 0%	B6	Life expectancy at birth in years (F/M): 75 / 68
B4	GDP (PPP int \$):	5000	B7	Number of 2nd sub-national administrative level divisions, name: 1493, Abadla
	Income status:	Lower middle income		

CODE	DataSet / Program	DataElement / Indicator	CatCombos / comments																																													
B1	DS_GeneralInformation	GEN_UN_WPP_Pop_Tot_1000 * 1000	It shows “No data” if no data value found.																																													
B2	DS_GeneralInformation	GEN_UN_WPP_Pop_Tot_AgeSex_1000 / B1	<table><tr><td>name</td><td>id</td></tr><tr><td>Under 5y, Female</td><td>o7NkWI5xFuS</td></tr><tr><td>5 to 9 y, Female</td><td>xodN5e1QCp6</td></tr><tr><td>10-14yr, Female</td><td>oic7kU2uVtJ</td></tr><tr><td>15 to 19 y, Female</td><td>adEelGXyPln</td></tr><tr><td>20 to 24 y, Female</td><td>SobJ4FGuBRA</td></tr><tr><td>25 to 29 y, Female</td><td>qdWOgC6bbBi</td></tr><tr><td>30 to 34 y, Female</td><td>IVFKF7NzjJa</td></tr><tr><td>35 to 39 y, Female</td><td>Jkrg1KI25AV</td></tr><tr><td>40 to 44 y, Female</td><td>i6rBoDsk4LE</td></tr><tr><td>45 to 49 y, Female</td><td>irBgvZTT9zq</td></tr><tr><td>50 to 54 y, Female</td><td>B2cv93OdJpl</td></tr><tr><td>55 to 59 y, Female</td><td>nJEkgZS74Tt</td></tr><tr><td>60 to 64 y, Female</td><td>RJDdLqVGxu8</td></tr><tr><td>65 to 69 y, Female</td><td>ECle1XHoHZ2</td></tr><tr><td>70 to 74 y, Female</td><td>Gh29gSpSYpp</td></tr><tr><td>75 to 79 y, Female</td><td>zvECz1sg3sj</td></tr><tr><td>80 to 84 y, Female</td><td>BO8BiFA6WZo</td></tr><tr><td>85 to 89 y, Female</td><td>hI8wdaiRHaS</td></tr><tr><td>90 to 94 y, Female</td><td>kH3O17Sezfp</td></tr><tr><td>95 to 99 y, Female</td><td>nHBTtdVMe7I</td></tr><tr><td>100 y and over, Female</td><td>gkeN62eQISA</td></tr></table>		name	id	Under 5y, Female	o7NkWI5xFuS	5 to 9 y, Female	xodN5e1QCp6	10-14yr, Female	oic7kU2uVtJ	15 to 19 y, Female	adEelGXyPln	20 to 24 y, Female	SobJ4FGuBRA	25 to 29 y, Female	qdWOgC6bbBi	30 to 34 y, Female	IVFKF7NzjJa	35 to 39 y, Female	Jkrg1KI25AV	40 to 44 y, Female	i6rBoDsk4LE	45 to 49 y, Female	irBgvZTT9zq	50 to 54 y, Female	B2cv93OdJpl	55 to 59 y, Female	nJEkgZS74Tt	60 to 64 y, Female	RJDdLqVGxu8	65 to 69 y, Female	ECle1XHoHZ2	70 to 74 y, Female	Gh29gSpSYpp	75 to 79 y, Female	zvECz1sg3sj	80 to 84 y, Female	BO8BiFA6WZo	85 to 89 y, Female	hI8wdaiRHaS	90 to 94 y, Female	kH3O17Sezfp	95 to 99 y, Female	nHBTtdVMe7I	100 y and over, Female	gkeN62eQISA
			name	id																																												
Under 5y, Female	o7NkWI5xFuS																																															
5 to 9 y, Female	xodN5e1QCp6																																															
10-14yr, Female	oic7kU2uVtJ																																															
15 to 19 y, Female	adEelGXyPln																																															
20 to 24 y, Female	SobJ4FGuBRA																																															
25 to 29 y, Female	qdWOgC6bbBi																																															
30 to 34 y, Female	IVFKF7NzjJa																																															
35 to 39 y, Female	Jkrg1KI25AV																																															
40 to 44 y, Female	i6rBoDsk4LE																																															
45 to 49 y, Female	irBgvZTT9zq																																															
50 to 54 y, Female	B2cv93OdJpl																																															
55 to 59 y, Female	nJEkgZS74Tt																																															
60 to 64 y, Female	RJDdLqVGxu8																																															
65 to 69 y, Female	ECle1XHoHZ2																																															
70 to 74 y, Female	Gh29gSpSYpp																																															
75 to 79 y, Female	zvECz1sg3sj																																															
80 to 84 y, Female	BO8BiFA6WZo																																															
85 to 89 y, Female	hI8wdaiRHaS																																															
90 to 94 y, Female	kH3O17Sezfp																																															
95 to 99 y, Female	nHBTtdVMe7I																																															
100 y and over, Female	gkeN62eQISA																																															
			<table><tr><td>name</td><td>id</td></tr><tr><td>Under 5y, Male</td><td>gWsMIgPOSzY</td></tr><tr><td>5 to 9 y, Male</td><td>lptUC1gVg8o</td></tr><tr><td>10-14yr, Male</td><td>o8dMMqNDctr</td></tr><tr><td>15 to 19 y, Male</td><td>xdAhLef7xG4</td></tr><tr><td>20 to 24 y, Male</td><td>ZYAx6PjJ2ZM</td></tr><tr><td>25 to 29 y, Male</td><td>AJkBK9XBytM</td></tr><tr><td>30 to 34 y, Male</td><td>xsUkVSOPK0u</td></tr><tr><td>35 to 39 y, Male</td><td>VwZsMBUBdR1</td></tr><tr><td>40 to 44 y, Male</td><td>XucrdYEMOE7</td></tr><tr><td>45 to 49 y, Male</td><td>BvCWylwlqa8</td></tr><tr><td>50 to 54 y, Male</td><td>RwwDYedBcDI</td></tr><tr><td>55 to 59 y, Male</td><td>xaMRyDOevEu</td></tr><tr><td>60 to 64 y, Male</td><td>Ss3gp5wAYOQ</td></tr><tr><td>65 to 69 y, Male</td><td>a2dH289sMou</td></tr><tr><td>70 to 74 y, Male</td><td>COVIpje6ADR</td></tr><tr><td>75 to 79 y, Male</td><td>MKDYDGdryXB</td></tr><tr><td>80 to 84 y, Male</td><td>Bpl46BM32FB</td></tr><tr><td>85 to 89 y, Male</td><td>avCYQARWeei</td></tr><tr><td>90 to 94 y, Male</td><td>PKDfpYDkyoy</td></tr><tr><td>95 to 99 y, Male</td><td>kXo51Sydk1t</td></tr><tr><td>100 y and over, Male</td><td>ttAEJltz1yh</td></tr></table>		name	id	Under 5y, Male	gWsMIgPOSzY	5 to 9 y, Male	lptUC1gVg8o	10-14yr, Male	o8dMMqNDctr	15 to 19 y, Male	xdAhLef7xG4	20 to 24 y, Male	ZYAx6PjJ2ZM	25 to 29 y, Male	AJkBK9XBytM	30 to 34 y, Male	xsUkVSOPK0u	35 to 39 y, Male	VwZsMBUBdR1	40 to 44 y, Male	XucrdYEMOE7	45 to 49 y, Male	BvCWylwlqa8	50 to 54 y, Male	RwwDYedBcDI	55 to 59 y, Male	xaMRyDOevEu	60 to 64 y, Male	Ss3gp5wAYOQ	65 to 69 y, Male	a2dH289sMou	70 to 74 y, Male	COVIpje6ADR	75 to 79 y, Male	MKDYDGdryXB	80 to 84 y, Male	Bpl46BM32FB	85 to 89 y, Male	avCYQARWeei	90 to 94 y, Male	PKDfpYDkyoy	95 to 99 y, Male	kXo51Sydk1t	100 y and over, Male	ttAEJltz1yh
name	id																																															
Under 5y, Male	gWsMIgPOSzY																																															
5 to 9 y, Male	lptUC1gVg8o																																															
10-14yr, Male	o8dMMqNDctr																																															
15 to 19 y, Male	xdAhLef7xG4																																															
20 to 24 y, Male	ZYAx6PjJ2ZM																																															
25 to 29 y, Male	AJkBK9XBytM																																															
30 to 34 y, Male	xsUkVSOPK0u																																															
35 to 39 y, Male	VwZsMBUBdR1																																															
40 to 44 y, Male	XucrdYEMOE7																																															
45 to 49 y, Male	BvCWylwlqa8																																															
50 to 54 y, Male	RwwDYedBcDI																																															
55 to 59 y, Male	xaMRyDOevEu																																															
60 to 64 y, Male	Ss3gp5wAYOQ																																															
65 to 69 y, Male	a2dH289sMou																																															
70 to 74 y, Male	COVIpje6ADR																																															
75 to 79 y, Male	MKDYDGdryXB																																															
80 to 84 y, Male	Bpl46BM32FB																																															
85 to 89 y, Male	avCYQARWeei																																															
90 to 94 y, Male	PKDfpYDkyoy																																															
95 to 99 y, Male	kXo51Sydk1t																																															
100 y and over, Male	ttAEJltz1yh																																															
B3	DS_GeneralInformation	NY.GDP.PCAP.PP.CD																																														
B4	DS_GeneralInformation	GEN WB IncomeGroup																																														

B5	DS_GeneralInformation	GEN_UN_WPP_Pop_Tot_AgeSex_1000	As B2, but also those Gender Unknown. Left: Under 5y, 5 to 9 y, 10-14yr Right: All the others.	
B6	DS_GeneralInformation	GEN_UN_WPP_LifeExpBirth_Female GEN_UN_WPP_LifeExpBirth_Male		
B7	Number of subdivisions in the orgUnitTree for the current country at the selected level. The name is the first occurrence found in the orgUnitTree.			

### 3.2 Epidemiology section

EPIDEMIOLOGY							
	VL	CL	ACL	ZCL	PKDL MCL		
C1 Endemicity status:	Non endemic	Previously endemic	Endemic	Endemic	Error!	Error!	
C2 Number of new cases (incidence):	25	15	100	50	No data	105	
C3 Number of relapse cases:	No data	1	No data	No data	N/A	N/A	
C4 Total number of cases:	25	18	100	50	No data	105	
C5 Imported cases (#, %):	No data, No data	21, 33%	No data, No data	No data, No data	N/A	N/A	
C6 Gender distribution (%F):	No data	33%	No data	No data	No data	99%	
C7 Age group distribution (% , <5/5-14/>14):	No data	(43, 47, 10)	No data	No data	No data	(100, No data, No data).	
C8 Incidence rate (cases/10 000 population in endemic areas):	0.01	0	-	-	N/A	N/A	
C9 Number of endemic 1st sub-national administrative level divisions (n):	9	47	No data	No data	N/A	N/A	
C10 Population at risk (% , n/total):	0% 1800 / 41320000	0% 9200 / 41320000	0% 0 / 41320000	0% 0 / 41320000	N/A	N/A	
C11 Was there any outbreak?	No data	Yes	No data	No data	N/A	N/A	
C12 Number of new foci:	No data	987	No data	No data	N/A	N/A	
N/A not applicable    VL = visceral leishmaniasis    CL = cutaneous leishmaniasis    ACL = anthroponotic cutaneous leishmaniasis    ZCL = zoonotic cutaneous leishmaniasis    PKDL = post-kala-azar dermal leishmaniasis    MCL = mucocutaneous leishmaniasis							


See detailed descriptions on table on next page. Codes are used when possible. Names or names and UIDs otherwise.

CODE	DataSet	DataElement / Indicator	CatCombos / Comments	
C1	GHO_NTDs	NTD_LEISHVEND NTD_LEISHCEND NTD_LEISHACEND NTD_LEISHZCEND NTD_LEISHMCEND NTD_LEISHPKDLEND	-	It replaces the numeric code (1,3 or 5) by "Endemic", "Previously endemic" or "Non endemic". It shows "Error!" if other code is found.
C2	DS_VL_Detailed_Annual DS_VL_Simple_Annual GHO_NTDs	VL_EPI_Type	New  (default for PKDL and MCL)	It shows "No data" if no data found in the system.
	DS_CL_Detailed_Annual DS_CL_Detailed_Monthly DS_CL_Simple_Annual GHO_NTDs	CL_EPI_Type MCL_GEN_EPID_cases		
	DS_ACL/ZCL_Detailed_Annual	ACL_EPI_Type ZCL_EPI_Type		
	DS_VL_Detailed_Annual DS_VL_Simple_Annual	PKDL_GEN_EPID_cases		
C3	*As C2 for each DE	VL_EPI_Type CL_EPI_Type ACL_EPI_Type ZCL_EPI_Type	Relapse (N/A for PKDL and MCL)	It shows "No data" if no data found in the system.
C4	*As C2 for each DE	VL_EPI_Type CL_EPI_Type ACL_EPI_Type ZCL_EPI_Type PKDL_GEN_EPID_cases MCL_GEN_EPID_cases	New Relapse Type unspecified (default for PKDL and MCL)	It shows "No data" if no data found in the system.
C5	DS_VL_Simple_Annual DS_VL_Detailed_Annual	VL_EPI_Type-Origin	New, Autochthonous Relapse, Autochthonous Type unspecified, Autochthonous New, Imported Relapse, Imported Type unspecified, Imported New, Origin unknown Relapse, Origin unknown Type unspecified, Origin unknown  LCPG shows - instead XY% if it was not able to calculate percentage.	
	DS_CL_Detailed_Annual DS_CL_Detailed_Monthly DS_CL_Simple_Annual	CL_EPI_Type-Origin		
	DS_ACL/ZCL_Detailed_Annual	ACL_EPI_Type-Origin		
		ZCL_EPI_Type-Origin		
C6	DS_VL_Detailed_Annual	VL_EPI_Type_Gender	name="New, Female" id="TtoYCIvCBA3" name="New, Gender Unknown" id="FaYhAikLX16" name="New, Male" id="GpQZH8hC7jY" name="Type unspecified, Female" id="wGED4K5Bs37" name="Type unspecified, Gender Unknown" id="zkKbllarKWM" name="Type unspecified, Male" id="aWWYWv6buzp"  LCPG shows - instead XY% if it was not able to calculate percentage.	
	DS_CL_Detailed_Monthly DS_CL_Detailed_Annual	CL_EPI_Type_Gender		
	DS_ACL/ZCL_Detailed_Annual	ACL_EPI_Type_Gender		
		ZCL_EPI_Type_Gender		
	DS_VL_Detailed_Annual	PKDL_EPID_sex	name="Female" id="V2LdgcGgFQt" name="Gender Unknown" id="jNbFhhnUsQv" name="Male" id="Z2hvpF7mhh7"	
	DS_CL_Detailed_Monthly DS_CL_Simple_Annual DS_CL_Detailed_Annual	MCL_EPID_sex		
C7	DS_VL_Detailed_Annual	VL_EPI_Type_Age	name="New, 15 y and over" id="DDliBAHqwGV" name="New, 5 to 14 y" id="mTyLqDjpQ5b" name="New, Age Unknown" id="dVuOzmU4xbl" name="New, Under 5y" id="hKq5WASZw8q" name="Type unspecified, 15 y and over" id="UQMTeRPY2U0" name="Type unspecified, 5 to 14 y" id="P6R9XEaqQbz" name="Type unspecified, Age Unknown" id="nlbrdHlIMKh"	
	DS_CL_Detailed_Monthly DS_CL_Detailed_Annual	CL_EPI_Type_Age		
	DS_ACL/ZCL_Detailed_Annual	ACL_EPI_Type_Age		
		ZCL_EPI_Type_Age		

			name="Type unspecified, Under 5y" id="rZwYGIqR8GG"	
	DS_VL_Detailed_Annual	PKDL_EPID_age	name="15 y and over" id="rN9ELJVdEpo" name="5 to 14 y" id="moktBQGym51" name="Age Unknown" id="gPGNI7bWhDB" name="Under 5y" id="HDXcEOGT2s1"	
	DS_CL_Detailed_Monthly	MCL_EPID_age		
	DS_CL_Simple_Annual DS_CL_Detailed_Annual			
C8	-	Value in C2 * 10000 / population at risk (numerator at C10)	If population at risk is 0, the incidence text show s N/A. N/A for PKDL and MCL.	
C9	Leishmaniasis endemicity	DET_VL_endemicity_WHO DET_CL_endemicity_WHO DET_ACL_endemicity_WHO DET_ZCL_endemicity_WHO	Gets the count of orgUnits at the selected subnational level in <b>CODEHERE</b> having "1" as value for the dataElement and year. N/A for PKDL and MCL.	
C10	-	VL_POP_AT_RISK_I CL_POP_AT_RISK_I ACL_POP_AT_RISK_I ZCL_POP_AT_RISK_I	Adds all the values at selected subnational level in <b>CODEHERE</b> . The indicator value is GEN_pop_Leish if the corresponding PI XXX_endemicity_WHO_factor1_PI equals 1. The indicator value is 0 otherwise.  LCPG shows - instead XY% if it was not able to calculate percentage.  N/A for PKDL and MCL.	
	DS_GeneralInformation	B1	Total population is same value as B1	
C11	DS_VL_Simple_Annual DS_VL_Detailed_Annual	VL_GEN_EPID_outbreak	default	Converts the boolean value to Yes/No text. N/A for PKDL and MCL.
	DS_CL_Detailed_Annual DS_CL_Simple_Annual	CL_GEN_EPID_outbreak		
	DS_ACL/ZCL_Detailed_Annual	ACL_GEN_EPID_outbreak ZCL_GEN_EPID_outbreak		
C12	DS_VL_Simple_Annual DS_VL_Detailed_Annual	VL_GEN_EPID_new focus	default	N/A for PKDL and MCL.
	DS_CL_Detailed_Annual DS_CL_Simple_Annual	CL_GEN_EPID_new focus		
	DS_ACL/ZCL_Detailed_Annual	ACL_GEN_EPID_new focus ZCL_GEN_EPID_new focus		

### 3.3 Monthly distribution of new cases January-December section

Monthly distribution of new cases January-December												
	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
D1 VL												
VL (previous year)	1909	1441	1441	1441	1441	1441	1441	1441	1441	1441	1441	1441
D2 CL	323	473	439	445	552	593	412	417	451	445	443	421
CL (previous year)	1661	1597	276									
D3 ACL	427	581	569	554	498	438	569	371	350	549	380	570
ACL (previous year)	1664	1865	101									
D4 ZCL	0	0	0	0	0	0	0	0	0	0	0	0
ZCL (previous year)	2300	1794	122									



CODE	Program	DataElement
D1	VL_cases_by provenance	VL_cases_byProvenance_T
D2	CL_cases_by provenance	CL_cases_byProvenance_T
D3		ACL_cases_byProvenance_T
D4		ZCL_cases_byProvenance_T


CODE	DataSet	DataElement / Indicator	CatCombos / Comments
D5	Same as in C2	VL_EPI_Type CL_EPI_Type ACL_EPI_Type ZCL_EPI_Type	Same as in C2, but data is retrieved from Analytics for last 15 years instead from raw data.

#### Incidence rates

INDICATOR	Numerator	denominator	Comments
IA VL EPI INC PopUN 10000	VL_cases_byProvenance_T	GEN_UN_WPP_Pop_Tot_1000 * 1000	indicatorType: Per ten thousand
IA CL EPI INC PopUN 10000	CL_cases_byProvenance_T		
IA ACL EPI INC PopUN 10000	ACL_cases_byProvenance_T		
IA ZCL EPI INC PopUN 10000	ZCL_cases_byProvenance_T		

### 3.4 Maps section

Distribution of VL/CL/ACL/ZCL cases per 10 000 population



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.  
Map production: WHO/HTM/NTD/IDM

INDICATOR	Numerator	denominator	Comments
VL EPI INC PopData LSH 10000	VL cases byProvenance T	GEN_pop_Leish (In Population data dataset)	<b>indicatorType:</b> Per ten thousand
CL EPI INC PopData LSH 10000	CL cases byProvenance T		
ACL EPI INC PopData LSH 10000	ACL cases byProvenance T		
ZCL EPI INC PopData LSH 10000	ZCL cases byProvenance T		

LEGENDSET name	Legend Name	startValue	endValue	Color
VL_INCIDENCE_LEGEND_0_10	No case reported	0.0	0.001	#CCFFCC
	0<1	0.001	1.0	#FFFFCC
	[1-2.5]	1.0	2.5	#FED976
	[2.5-10]	2.5	10.0	#FC4E2A
	≥10	10.0	10000.0	#800026
CL_INCIDENCE_LEGEND_0_100 ACL_INCIDENCE_LEGEND_0_100 ZCL_INCIDENCE_LEGEND_0_100	No case reported	0.0	0.001	#CCFFCC
	0<10	0.001	10.0	#FFFFCC
	[10-50]	10.0	50.0	#FED976
	[50-100]	50.0	100.0	#FC4E2A
	≥100	100.0	10000.0	#800026

### 3.5 Control and surveillance section

#### CONTROL AND SURVEILLANCE

G1	Year Leishmaniasis National Control Programme (LNCP) was established:	2001	G5	Year latest national guidelines (CL / VL):	No data / No data
G2	Type of surveillance (CL / VL):	No data / Integrated	G6	Is leishmaniasis notifiable (mandatory report)? (CL / VL):	No data / No data
G3	Is there a vector control programme?	Yes	G7	Is there a reservoir host control programme?	Yes
G4	Type of insecticide used for Indoor residual Spraying (IRS):	101	G8	Number of leishmaniasis health facilities (CL / VL):	No data / No data

CODE	DataSet	DataElement / Indicator	Comments
G1	DS_VL_Detailed_Annual DS_CL_Detailed_Annual DS_ACL/ZCL_Detailed_Annual	Leish_GEN_LNCP_year	It shows "No data" when no entry found in the system.
G2	DS_CL_Detailed_Annual DS_VL_Detailed_Annual	CL_GEN_Surv_Type VL_GEN_Surv_Type	Converts codes into texts: 1: Vertical 2: Integrated 7: Other 8: Non-applicable 9: Unknown
G3	DS_CL_Detailed_Annual DS_ACL/ZCL_Detailed_Annual DS_VL_Detailed_Annual	Leish_GEN_VectorControl	Converts codes into texts: 1: Yes 2: No 9: Unknown
G4		Leish_GEN_VectorControl_Insecticide	It shows "No data" when no entry found in the system.
G5	DS_ACL/ZCL_Detailed_Annual DS_CL_Detailed_Annual VL_GEN_Guidelines_year	CL_GEN_Guidelines_year VL_GEN_Guidelines_year	It shows "No data" when no entry found in the system.
G6	DS_CL_Detailed_Annual DS_ACL/ZCL_Detailed_Annual DS_VL_Detailed_Annual	CL_GEN_Surv_Notif VL_GEN_Surv_Notif	Converts codes into texts: 1: Yes 2: No 9: Unknown
G7	DS_CL_Detailed_Annual DS_ACL/ZCL_Detailed_Annual DS_VL_Detailed_Annual	Leish_GEN_ReservoirControl	Converts codes into texts: 1: Yes 2: No 9: Unknown
G8	DS_CL_Detailed_Annual	CL_GEN_Surv_HF VL_GEN_Surv_HF	It shows "No data" when no entry found in the system.



### 3.6 Diagnosis section

DIAGNOSIS		VL	CL	ACL	ZCL	PKDL	MCL
H1	Number of people screened actively for:	No data	No data	N/A	N/A	N/A	N/A
H2	Number of people screened passively for:	No data	N/A	N/A	N/A	N/A	N/A
H3	VL cases diagnosed by RDT* (%, RDT+/total VL cases):	86% (216 / 252)	N/A	N/A	N/A	N/A	N/A
H4	Proportion of positive RDT* (%, RDT+/total RDT):	100% (216 / 216)	N/A	N/A	N/A	N/A	N/A
H5	Cases diagnosed by direct exam (parasitology) (%, # slides +/-total cases):	15% (38 / 252)	No data	N/A	N/A	N/A	N/A
H6	Proportion of positive slides (%, # slides +/-total slides):	100% (38 / 38)	No data	No data	No data	N/A	N/A
H7	Cases diagnosed clinically (%, # clinical cases/total cases):	0% (0 / 252)	No data	N/A	N/A	N/A	N/A
H8	Percentage of cases with HIV-VL coinfection:	0% (0 / 252)	N/A	N/A	N/A	N/A	N/A
<small>N/A not applicable    VL = visceral leishmaniasis    CL = cutaneous leishmaniasis    ACL = anthroponotic cutaneous leishmaniasis    ZCL = zoonotic cutaneous leishmaniasis    PKDL = post-kala-azar dermal leishmaniasis    MCL = mucocutaneous leishmaniasis    HIV = human immunodeficiency virus</small>		<small>* These indicators apply only for primary VL cases    RDT = rapid diagnostic test</small>					

CODE	DataSet	DataElement / Indicator	CatCombos / Comments	
H1	DS_VL_Detailed_Annual	VL_SCREEN_active	-	N/A for PKDL and MCL
	DS_CL_Detailed_Monthly	CL_SCREEN_active		
	DS_CL_Detailed_Annual			
	DS_ACL/ZCL_Detailed_Annual	ACL_SCREEN_active ZCL_SCREEN_active		
H2	DS_VL_Detailed_Annual	VL_SCREEN_passive	-	this DE is assigned to the dataset but it's not in the form!
	DS_CL_Detailed_Monthly	CL_SCREEN_passive	-	This DE is not assigned to the dataset!
	DS_CL_Detailed_Annual		-	
	DS_ACL/ZCL_Detailed_Annual	ACL_SCREEN_passive ZCL_SCREEN_passive	-	these DE are assigned to the dataset but they are not in the form! N/A for PKDL and MCL
H3	DS_VL_Detailed_Annual	VL_Lab_RDT_results_type	name="New, Positive" id="jRcT6HVkb2t" name="Type unspecified, Positive" id="YXktM46YiXo"	VL_Lab_RDT_results_type (New + Unsp.) / Total new and unsp. cases  N/A for CL (All types) and PKDL.
H4	DS_VL_Detailed_Annual	VL_Lab_RDT_tested_type	name="New" id="psVSPLclyFj" name="Type unspecified" id="IRW4YrOtk5q"	VL_Lab_RDT_results_type (New + Unsp.) / VL_Lab_RDT_tested_type (New + Unsp.)
		VL_Lab_RDT_results_type	name="New, Positive" id="jRcT6HVkb2t" name="Type unspecified, Positive" id="YXktM46YiXo"	N/A for CL (All types) and PKDL.

H5	DS_VL_Detailed_Annual	VL_Lab_parasito_tested_type	New Relapse Type unspecified	Direct exam diagnosed / Total cases (C4)
	DS_CL_Detailed_Annual DS_ACL/ZCL_Detailed_Monthly	CL_LAB_parasito_Suspects		
	DS_ACL/ZCL_Detailed_Annual	ACL_Lab_Parasito_Results ZCL_Lab_Parasito_Results		
H6	DS_VL_Detailed_Annual	VL_LAB_parasito_result_type	name="New, Positive" id="jRcT6HVKb2t" name="Relapse, Positive" id="QKqVJ13mGZI" name="Type unspecified, Positive" id="YXktM46YiXo"	Direct exam diagnosed / Direct exam diagnoses (numerator on H5)
	DS_CL_Detailed_Annual DS_ACL/ZCL_Detailed_Monthly	CL_LAB_Parasito_Results		
	DS_ACL/ZCL_Detailed_Annual	ACL_Lab_Parasito_Results ZCL_Lab_Parasito_Results		
H7	DS_VL_Detailed_Annual	VL_LAB_clinical	New Relapse Type unspecified	Clinical cases / Total cases (C4)
	DS_CL_Detailed_Annual DS_ACL/ZCL_Detailed_Monthly	NO DATA ELEMENT		
	DS_ACL/ZCL_Detailed_Annual	NO DATA ELEMENT NO DATA ELEMENT		
H8	DS_VL_Detailed_Annual	VL_LAB_HIVstatus_Type	name="New, Positive" id="jRcT6HVKb2t" name="Relapse, Positive" id="QKqVJ13mGZI" name="Type unspecified, Positive" id="YXktM46YiXo"	VL_LAB_HIVstatus_Type (New Positive + Relapse Positive+Unsp. Positive) / Total cases (C4)

### 3.7 Treatment and medicines and Treatment Outcome section

#### TREATMENT AND MEDICINES

I1	Is treatment provided for free in the public sector? (CL / VL):	N/A / Yes
I2	Antileishmanial medicines included in the National Medicine List:	Amphotericin B deoxycholate, Miltefosine, Paromomycin, Sodium stibogluconate (SSG)
<b>INITIAL TREATMENT OUTCOME FOR NEW CASES</b>		
I3	Proportion of cases treated (% , # treated cases/ total cases):	VL 98% (247 / 252) CL N/A ACL N/A ZCL N/A
I4	Initial cure rate (% , # cases initially cured /total cases):	96% (243 / 252) N/A N/A N/A
I5	Failure rate (% , # patients with treatment failure /total cases):	0% (0 / 252) N/A N/A N/A
I6	Case fatality rate (% , # patients who died/ total cases):	2% (4 / 252) N/A N/A N/A

I1	DS_VL_Detailed_Annual DS_CL_Detailed_Annual DS_ACL/ZCL_Detailed_Annual	VL_GEN_TxFree CL_GEN_TxFree	Converts codes into texts: 1: Yes 2: No 9: Unknown
I2	DS_VL_Detailed_Annual DS_CL_Detailed_Annual DS_ACL/ZCL_Detailed_Annual	Leish_GEN_EML_AmphotericinB Leish_GEN_EML_LiposomalAmp Leish_GEN_EML_Meglumine Leish_GEN_EML_Miltefosine Leish_GEN_EML_Paromomycin Leish_GEN_EML_Pentamidine Leish_GEN_EML_SSG	LCPG retrieves ids and replaced by hardcodes names: Amphotericin B deoxycholate Liposomal amphotericin B Meglumine antimoniate Miltefosine Paromomycin Pentamidine Sodium stibogluconate (SSG)
I3	DS_VL_Detailed_Annual	VL_TREAT_completed	Treatment completed, New, Ambisome Treatment completed, New, Antimonials Treatment completed, New, Other VL drug Treatment completed, New, SSG + Paramomycin Treatment completed, New, VL drug unspecified Treatment completed, Type unspecified, Ambisome Treatment completed, Type unspecified, Antimonials Treatment completed, Type unspecified, Other VL drug Treatment completed, Type unspecified, SSG + Paramomycin Treatment completed, Type unspecified, VL drug unspecified  Treatment stopped (adverse event, death...), New, Ambisome Treatment stopped (adverse event, death...), New, Antimonials Treatment stopped (adverse event, death...), New, Other VL drug Treatment stopped (adverse event, death...), New, SSG + Paramomycin Treatment stopped (adverse event, death...), New, VL drug unspecified Treatment stopped (adverse event, death...), Type unspecified, Ambisome Treatment stopped (adverse event, death...), Type unspecified, Antimonials Treatment stopped (adverse event, death...), Type unspecified, Other VL drug Treatment stopped (adverse event, death...), Type unspecified, SSG + Paramomycin Treatment stopped (adverse event, death...), Type unspecified, VL drug unspecified  Defaulter, New, Ambisome Defaulter, New, Antimonials Defaulter, New, Other VL drug Defaulter, New, SSG + Paramomycin Defaulter, New, VL drug unspecified Defaulter, Type unspecified, Ambisome Defaulter, Type unspecified, Antimonials Defaulter, Type unspecified, Other VL drug Defaulter, Type unspecified, SSG + Paramomycin Defaulter, Type unspecified, VL drug unspecified  Treatment completion unknown, New, Ambisome Treatment completion unknown, New, Antimonials Treatment completion unknown, New, Other VL drug Treatment completion unknown, New, SSG + Paramomycin Treatment completion unknown, New, VL drug unspecified Treatment completion unknown, Type unspecified, Ambisome Treatment completion unknown, Type unspecified, Antimonials Treatment completion unknown, Type unspecified, Other VL drug Treatment completion unknown, Type unspecified, SSG + Paramomycin Treatment completion unknown, Type unspecified, VL drug unspecified
	DS_CL_Detailed_Annual	CL_TREAT_completed	Treatment completed, New, Meglumine Antimoniate (glucantime)

	DS_ACL/ZCL_Detailed_Annual	ACL_TREAT_completed ZCL_TREAT_completed	<p>Treatment completed, New, Other CL drug Treatment completed, New, SSG Treatment completed, New, Treatment Drug Unknown</p> <p>Treatment completed, Type unspecified, Meglumine Antimoniate (glucantime) Treatment completed, Type unspecified, Other CL drug Treatment completed, Type unspecified, SSG Treatment completed, Type unspecified, Treatment Drug Unknown</p> <p>Treatment stopped (adverse event, death...), New, Meglumine Antimoniate (glucantime) Treatment stopped (adverse event, death...), New, Other CL drug Treatment stopped (adverse event, death...), New, SSG Treatment stopped (adverse event, death...), New, Treatment Drug Unknown</p> <p>Treatment stopped (adverse event, death...), Type unspecified, Meglumine Antimoniate (glucantime) Treatment stopped (adverse event, death...), Type unspecified, Other CL drug Treatment stopped (adverse event, death...), Type unspecified, SSG Treatment stopped (adverse event, death...), Type unspecified, Treatment Drug Unknown Defaulter, New, Meglumine Antimoniate (glucantime) Defaulter, New, Other CL drug Defaulter, New, SSG Defaulter, New, Treatment Drug Unknown Defaulter, Type unspecified, Meglumine Antimoniate (glucantime) Defaulter, Type unspecified, Other CL drug Defaulter, Type unspecified, SSG Defaulter, Type unspecified, Treatment Drug Unknown Treatment completion unknown, New, Meglumine Antimoniate (glucantime) Treatment completion unknown, New, Other CL drug Treatment completion unknown, New, SSG Treatment completion unknown, New, Treatment Drug Unknown Treatment completion unknown, Type unspecified, Meglumine Antimoniate (glucantime) Treatment completion unknown, Type unspecified, Other CL drug Treatment completion unknown, Type unspecified, SSG Treatment completion unknown, Type unspecified, Treatment Drug Unknown</p>
14	DS_VL_Detailed_Annual DS_CL_Detailed_Monthly DS_CL_Detailed_Annual DS_ACL/ZCL_Detailed_Annual	VL_INIT_ITxO_Drug_Type CL_ITxO_Tx-route ACL_ITxO_Tx-drug ZCL_ITxO_Tx-drug	<p>Ambisome, New, Initial Cure Ambisome, Type unspecified, Initial Cure Antimonials, New, Initial Cure Antimonials, Type unspecified, Initial Cure Meglumine Antimoniate (glucantime), New, Initial Cure Meglumine Antimoniate (glucantime), Type unspecified, Initial Cure Other CL drug, New, Initial Cure Other CL drug, Type unspecified, Initial Cure Other VL drug, New, Initial Cure Other VL drug, Type unspecified, Initial Cure SSG, New, Initial Cure SSG + Paramomycin, New, Initial Cure SSG + Paramomycin, Type unspecified, Initial Cure SSG, Type unspecified, Initial Cure Treatment Drug Unknown, New, Initial Cure Treatment Drug Unknown, Type unspecified, Initial Cure VL drug unspecified, New, Initial Cure VL drug unspecified, Type unspecified, Initial Cure</p>
15			<p>Ambisome, New, Failure Ambisome, Type unspecified, Failure Antimonials, New, Failure Antimonials, Type unspecified, Failure Meglumine Antimoniate (glucantime), New, Failure Meglumine Antimoniate (glucantime), Type unspecified, Failure Other CL drug, New, Failure Other CL drug, Type unspecified, Failure Other VL drug, New, Failure Other VL drug, Type unspecified, Failure SSG, New, Failure SSG + Paramomycin, New, Failure SSG + Paramomycin, Type unspecified, Failure SSG, Type unspecified, Failure Treatment Drug Unknown, New, Failure Treatment Drug Unknown, Type unspecified, Failure VL drug unspecified, New, Failure VL drug unspecified, Type unspecified, Failure</p>
16			<p>Ambisome, New, Death Ambisome, Type unspecified, Death Antimonials, New, Death Antimonials, Type unspecified, Death Meglumine Antimoniate (glucantime), New, Death Meglumine Antimoniate (glucantime), Type unspecified, Death Other CL drug, New, Death Other CL drug, Type unspecified, Death Other VL drug, New, Death</p>

			Other VL drug, Type unspecified, Death SSG, New, Death SSG + Paramomycin, New, Death SSG + Paramomycin, Type unspecified, Death SSG, Type unspecified, Death Treatment Drug Unknown, New, Death Treatment Drug Unknown, Type unspecified, Death VL drug unspecified, New, DeathVL drug unspecified, Type unspecified, Death
--	--	--	--